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ABSTRACT
 
Introduction: Several recent randomized clinical trials have evaluated hypofraction-
ated regimens against conventionally fractionated EBRT and shown similar effective-
ness with conflicting toxicity results. The current view regarding hypofractionation 
compared to conventional EBRT among North American genitourinary experts for 
management of prostate cancer has not been investigated.
Materials and Methods: A survey was distributed to 88 practicing North American GU 
physicians serving on decision - making committees of cooperative group research 
organizations. Questions pertained to opinions regarding the default EBRT dose and 
fractionation for a hypothetical example of a favorable intermediate - risk prostate 
cancer (Gleason 3 + 4). Treatment recommendations were correlated with practice pat-
terns using Fisher’s exact test.
Results: Forty - two respondents (48%) completed the survey. We excluded from analy-
sis two respondents who selected radical hypofractionation with 5 - 12 fractions as a 
preferred treatment modality. Among the 40 analyzed respondents, 23 (57.5%) recom-
mend conventional fractionation and 17 (42.5%) recommended moderate hypofrac-
tionation. No demographic factors were found to be associated with preference for a 
fractionation regimen. Support for brachytherapy as a first choice treatment modality 
for low - risk prostate cancer was borderline significantly associated with support for 
moderate hypofractionated EBRT treatment modality (p = 0.089).
Conclusions: There is an almost equal split among North American GU expert radia-
tion oncologists regarding the appropriateness to consider moderately hypofraction-
ated EBRT as a new standard of care in management of patients with prostate cancer. 
Physicians who embrace brachytherapy may be more inclined to support moderate 
hypofractionated regimen for EBRT. It is unclear whether reports with longer follow-
ups will impact this balance, or whether national care and reimbursement policies 
will drive the clinical decisions. In the day and age of patient - centered care delivery, 
patients should receive an objective recommendation based on available clinical evi-
dence. The stark division among GU experts may influence the design of future clinical 
trials utilizing EBRT for patients with prostate cancer.
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INTRODUCTION
The standard eight-to-nine week course 
of conventional external beam radiation thera-
py (EBRT) for prostate cancer although effective, 
disrupts patients’ normal lives, causes financial 
toxicity to patients and places a significant fi-
nancial strain on the healthcare system. For these 
reasons, hypofractionated radiation therapy (RT), 
which involves larger radiation doses administe-
red over an overall shorter time period, has in-
creased in popularity, and has been established 
in other disease sites, such as breast cancer, bone 
metastases, bladder cancer, glioblastoma and 
non - small cell lung cancer (1-5). Four rando-
mized clinical trials have compared moderately 
fractionated regimens to conventionally fractio-
nated RT in prostate cancer (Table-1) (6-11). With 
5-years of follow-up, none revealed inferiority 
of hypofractionation regarding the treatment 
outcomes, and the toxicity reports are contra-
dictory, with no overwhelming and reproducible 
toxicity associated with a moderately hypofrac-
tionated regimens using 2.5 to 3 Gy per fraction. 
We sought to determine the current view of mo-
derate hypofractionation among North American 
genitourinary (GU) radiation oncology experts 
due to their influence in shaping the direction of 
national guidelines.
MATERIALS AND METHODS
Survey design and deployment
 The survey was designed to assess the 
opinions of GU experts on the default EBRT dose 
and fractionation for a hypothetical patient with 
a favorable - intermediate risk prostate cancer 
who would require by most current conventions 
EBRT to prostate alone without prophylactic ir-
radiation of pelvic lymph nodes. Three fractiona-
tion schemes were offered as choices: conventio-
nal fractionation (78 Gy in 2 Gy fractions, 79.2 
Gy in 1.8 Gy fractions or equivalent), moderate 
hypofractionation (70 Gy in 2.5 Gy fractions or 
equivalent), or SBRT / radical hypofractionation 
(5 - 12 fractions or equivalent). The study was ap-
proved by IRB and electronically sent to 88 Nor-
th American GU oncology physicians, who ser-
ve on cooperative group research organizations 
such as NRG Oncology. The survey was designed 
and hosted by Research Electronic Data Captu-
re (REDCap), and contained screening questions 
to ensure respondents were currently practicing, 
not in training, and specializing in GU oncolo-
gy (12). A copy of the survey is available in the 
Appendix 1.
Statistical analysis
 Based on responses, participants were 
categorized as “supporters” or “opponents” of 
moderate hypofractionation. For the purposes of 
this study, only responders choosing conventio-
nal fractionation or moderate hypofractionation 
were included. Fisher’s exact test was used to 
determine whether treatment recommendations 
were correlated with practice patterns. R (R ver-
sion 3.3.3 (2017-03-06)) was used for all data 
analysis. Statistical significance was set at p < 
0.05.
RESULTS
 Forty - two of the 88 radiation oncolo-
gists completed the survey, of whom 40 (95.2%) 
recommended either conventional fractionation 
or moderate hypofractionation; two (4.8%) re-
commended stereotactic body radiation thera-
py (SBRT) (Figure-1) and were excluded from 
the analysis. Of 40 analyzable respondents, 23 
(57.5%) recommended conventional fractiona-
tion and 17 (42.5%) recommended moderate hy-
pofractionation.
 No demographic factors (years in practi-
ce, geographic location of residency, geographic 
location of practice, monthly patient volume, 
practice type) as well as other clinical positions 
(active surveillance recommendation preference, 
brachytherapy boost advocacy, self-identifica-
tion as an expert brachytherapist, likelihood of 
considering stereotactic body RT for oligometas-
tatic disease, likelihood of prophylactically irra-
diating pelvic lymph nodes, support of advanced 
imaging techniques) were significantly associa-
ted with support of moderate hypofractionation. 
Only the choice of brachytherapy as a preferred 
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treatment option for patients with low - risk 
prostate cancer approached significance for re-
commendation of hypofractionation (p = 0.089) 
(Table-2).
DISCUSSION
 Biological considerations of a markedly 
lower alpha / beta ratio of prostate cancer in 
comparison to surrounding normal tissues led 
researchers to clinical investigation of hypo-
fractionated regimens in management of pa-
tients with prostate cancer with EBRT (13). Four 
large international randomized clinical trials 
have established non - inferiority of modera-
te hypofractionation (2.5 - 3 Gy per fraction), 
with varying toxicity results, some supporting 
conventional, others hypofractionated regi-
mens, but none reporting overwhelming toxi-
city within the 5 - years of a follow-up period 
(Table-1) (6-11).
 The degree of acceptance / rejection of 
treatment modalities in North America is to a 
significant extent shaped by opinions of leading 
academic physicians who define and periodically 
update national treatment guidelines, author con-
sensus statements and shape the future clinical 
trial protocols. Because of this influence, we sou-
ght to determine the acceptance of hypofractio-
nation for prostate cancer among North American 
GU radiation oncology experts (14).
 The results of this study indicate that 
hypofractionated EBRT, defined as 70 Gy in 
2.5 Gy fractions or an equivalent regiment, has 
made significant inroads among North Ame-
rican GU experts in the treatment of prostate 
cancer, as more than 40% of experts recom-
mended hypofractionated EBRT as their pre-
ferred EBRT treatment modality. Nevertheless, 
55% of experts still consider conventionally 
fractionated EBRT as an unchallenged standard 
of care. Physicians who embrace a shorter tre-
atment modality (brachytherapy), despite pos-
sible increase in acute toxicity - also tend to 
support hypofractionated EBRT. The relative-
ly even duality regarding conventional versus 
hypofractionated treatment recommendation 
for intermediate - risk prostate cancer despite 
the four randomized trials already published on 
this topic (6-9) speaks to the issue that rando-
mized trials do not necessarily change the stan-
dard of care, particularly in the United States, 
and a significantly longer follow-up is requi-
red; this duality is reflected in the most updated 
clinically localized prostate cancer guidelines 
published jointly by the American Urological 
Association, American Society for Radiation 
Oncology (ASTRO), and the Society of Urologic 
Oncology (15, 16). Hypofractionation in breast 
cancer similarly was adopted in other countries 
much sooner than in the United States, where 
ASTRO consensus statements, educational ses-
sions and even direct advertisement to patients 
regarding hypofractionated options and their 
non - inferiority, led to final acceptance of hy-
pofractionation as a new standard of care. It is 
unclear whether reimbursement system in the 
U.S. is partially responsible for a slower update 
of shorter treatment courses. Limitations of this 
study are relatively small sample size, despi-
te an impressive (but still below fifty percent) 
response rate, inability to capture a full range 
of options due to multiple choice format, and 
a lack of granularity in addressing the impact 
of racial demographic of patients being treated 
(17). Furthermore, the absence of decade - long 
toxicity and outcome data comparing conven-
tional versus moderate hypofractionation pro-
vides an uncertainty of outcomes beyond the 
five years of currently published results (6-11).
 In conclusion, there is currently a near-
ly even split between radiation oncology experts 
in North America recommending conventionally 
fractionated vs moderately hypofractionated 
EBRT for patients with prostate cancer, based on 
dramatically different interpretation of results of 
4 randomized clinical trials. Longer follow-up of 
these trials may impact the balance, while natio-
nal care and reimbursement policies may influen-
ce the accepted standard of care.
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Table 1 - Summary of the four randomized clinical trials comparing hypofractionation (H-RT) with conventional fractionation 
(C-RT) for prostate cancer (OS = overall survival; DFS = disease-free survival; RFS = relapse-free survival; GU = genitourinary; 
GI = gastrointestinal; CI = confidence interval).
Trial Hypofractionation regimen Follow-up 
duration
Location Differences in 
OS or DFS
Differences 
in GU toxicity 
between 
modalities
Differences 
in GI toxicity 
between 
modalities
RTOG 
0415 
(7)
2.5 Gy x 28 5 years USA No No 
(late GU trended 
toward favoring 
C-RT: p=0.06)
Yes
(late GI: 
p=0.002 
favored C-RT)
CHHiP 
(8)
3 Gy x 20; 
3 Gy x 19
5 years UK, Ireland, 
Switzerland, 
New Zealand
No No Yes (acutely 
favoring C-RT; 
none by week 
18)
PROFIT 
(6)
3 Gy x 20 5 years Canada, 
Australia, France
No No (acutely; late 
toxicity favored 
H-RT)
No (acutely; 
late toxicity 
favored H-RT)
HYPRO 
(9-11)
3.4 Gy x 19 5 years Netherlands No Yes (H-RT 
inferior for 
acute and 
late grade 3+ 
toxicity)
Yes (H-RT 
inferior for 
acute but not 
late grade 3+ 
toxicity)
Trial GU toxicity
(H-RT)
GU toxicity
(C-RT)
GI toxicity 
(H-RT)
GI toxicity 
(C-RT)
Disease control 
(H-RT)
Disease control 
(C-RT)
RTOG 
0415 
(7)
Early grade 
2-4 GU = 
147/545
Late grade 
2-4 GU = 
161/545
Early grade 
2-4 GU = 
145/534
Late grade 
2-4 GU = 
121/534
Early grade 
2-4 GI = 
58/545
Late grade 
2-4 GI = 
121/545
Early 
grade 
2-4 GI = 
55/534
Late grade 
2-4 GI = 
75/534
86.3% DFS (95% CI: 83.1-
89.0)
85.3% DFS (95% CI: 81.9-
88.1)
CHHiP 
(8)
Early grade 
2-4 GU = 
46-49%
Late grade 
2-4 GU = 
6.6-11.7%
Early grade 
2-4 GU = 
46%
Late grade 
2-4 GU = 
9.1%
Early grade 
2-4 GI = 
38%
Late grade 
2-4 GI 
= 11.3-
11.9%
Early 
grade 2-4 
GI = 25%
Late grade 
2-4 GI = 
13.7%
85.9-90.6% biochemical/
clinical failure freedom
88.3% biochemical/clinical 
failure freedom
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PROFIT 
(6)
Early grade 
2-4 GU = 
185/608
Late grade 
2-4 GU = 
136/608
Early grade 
2-4 GU = 
183/598
Late grade 
3-4 GU = 
134/598
Early grade 
2-4 GI = 
99/608
Late grade 
2-4 GI = 
54/608
Early 
grade 
2-4 GI = 
62/598
Late grade 
2-4 GI = 
83/598
85% DFS 85% DFS
HYPRO 
(9-11)
Early grade 
2-4 GU = 
75/410
Late grade 
2-4 GU at 
three years 
= 163/395
Early grade 
2-4 GU = 
73/410
Late grade 
3-4 GU at 
three years 
= 151/387
Early grade 
2-4 GI = 
42/410
Late grade 
2-4 GI at 
three years 
= 86/395
Early 
grade 
2-4 GI = 
43/410
Late grade 
2-4 GI 
at three 
years = 
68/387
80.5% five-year RFS (95% 
CI: 75.7-84.4)
77.1% five-year RFS (95% CI: 
71.9-81.5)
Figure 1 - Default External Beam Radiation Therapy Fractionation used by North American genitourinary oncology expert 
radiation oncologists for treatment of a hypothetical patient with a favorable intermediate risk Prostate Cancer (Gleason 3+4).
PCa = prostate cancer; hypo = hypofractionation
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Table 2 - Association between clinical practice recommendations and choice of default dose/fractionation for Gleason 3+4 
prostate adenocarcinoma.
Clinical Scenario Clinical Practice 
Recommendation
Conventional 
Fractionation 
(78 Gy in 2 Gy 
fractions, 79.2 Gy in 
1.8 Gy fractions, or 
equivalent)
Moderate 
Hypofractionation 
(70 Gy in 2.5 Gy fractions 
or equivalent)
P value
Active surveillance recommendation 
for Gleason 6 disease
Yes 21 (91.3%) 17 (100%) 0.546
No 2 (8.7%) 0 (0%)
Active surveillance recommendation 
for Gleason 3+4 disease
Yes 3 (13.0%) 4 (23.5%) 0.607
No 20 (87.0%) 13 (76.5%)
SBRT for oligometastatic lesions Yes 18 (78.3%) 12 (70.6%) 0.837
No 5 (21.7%) 5 (29.4%)
Treatment of pelvic lymph nodes in 
localized high-risk prostate cancer
Rarely 9 (39.1%) 4 (23.5%) 0.377
Often 14 (60.9%) 13 (76.5%)
Treatment of high-risk prostate cancer EBRT+ADT 15 (65.2%) 7 (41.2%) 0.305
EBRT+ADT+
brachytherapy boost
8 (34.8%) 10 (58.8%)
Believer in advanced-imaging (Novel 
ligand-based PET imaging)
Yes 14 (60.9%) 14 (82.4%) 0.137
No 9 (39.1%) 2 (11.8%)
First choice for treatment of Gleason 6 
disease who desires intervention
Brachytherapy 8 (34.8%) 12 (70.6%) 0.089
EBRT 5 (21.7%) 1 (5.9%)
No preference 10 (43.5%) 4 (23.5%)
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Advanced imaging techniques in prostate cancer
Please complete the survey below. It is 4 pages long and should take approximately 5 minutes to finish.
Thank you very much for your contribution!
Are you actively practicing clinical oncology?
Yes No
Is genitourinary oncology your primary focus?
Yes No
What is your specialty?
Radiation oncology
Medical oncology/Hematology oncology
Urology
None of the above
How many years has it been since you completed training (residency/oncology fellowship)?
0-4 years
5-10 years
11-20 years
>20 years
Still in training
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Where do you primarily practice?
Canada
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Other
How would you best describe your primary practice setting?
Academic/university
Hospital-based, no academic/university affiliation
Free-standing, no academic/university affiliation
Government employed, such as VA, military, or government-run facility
Other
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Where did you complete your training?
Canada
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Other
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For each of the following patient scenarios, please enter the lowest PSA value at which you
would order a C-11 PET or PSMA PET.  Enter 0 for "never."
Gleason 4+5=9, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 4+3=7, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 10, T3, intact prostate, pre-treatment __________________________________
Gleason 4+3=7, T2, intact prostate, pre-treatment __________________________________
Gleason 10, T3, post-definitive radiation __________________________________
Gleason 4+3=7, T2, post-definitive radiation __________________________________
In a patient with newly diagnosed cT2 Gleason 9 prostate cancer with a PSA of 200 ng/mL, who has no evidence of
bone metastases by nuclear bone scan and abdominopelvic CT, which of the following would you consider for further
workup?
C-11 PET
PSMA PET
No further workup prior to therapy
Other (specify)
Please specify
 
__________________________________
What are the reasons you do not order PSMA PET or C-11 PET more frequently? (Check all that apply)
Availability
Cost
Lack of evidence
Unsure how to interpret
Other (specify)
Please specify
 
__________________________________
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Where do you primarily practice?
Canada
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Other
How would you best describe your primary practice setting?
Academic/university
Hospital-based, no academic/university affiliation
Free-standing, no academic/university affiliation
Government employed, such as VA, military, or government-run facility
Other
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Nebraska
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South Carolina
South Dakota
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How w uld you best describe your primary practice setting?
Academic/university
Hospital-based, no academic/university affiliation
Free-standing, no academic/university affiliation
Government employed, such as VA, military, or government-run facility
Other
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How many patients with prostate cancer do you see in consultation per month on average?
0-4
5-9
10-14
15-20
>20
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For each of the following patient scenarios, please enter the lowest PSA value at which you
would order a C-11 PET or PSMA PET.  Enter 0 for "never."
Gleason 4+5=9, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 4+3=7, post-prostatectomy, onsecutively __________________________________
rising PSA
Gleason 10, T3, intact prostate, pre-treatment __________________________________
Gleason 4+3=7, T2, intact prostate, pre-treatment __________________________________
Gleason 10, T3, post-definitive radiation __________________________________
Gleason 4+3=7, T2, post-definitive radiation __________________________________
In a patient with newly diagnosed cT2 Gleason 9 prostate cancer with a PSA of 200 ng/mL, who has no evidence of
bone metastases by nuclear bone scan and abdominopelvic CT, which of the following would you consider for further
workup?
C-11 PET
PSMA PET
No further workup prior to therapy
Other (specify)
Please specify
 
__________________________________
What are the reasons you do not order PSMA PET or C-11 PET more frequently? (Check all that apply)
Availability
Cost
Lack of evidence
Unsure how to interpret
Other (specify)
Please specify
 
__________________________________
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 Please tell us more about your practice characteristics.
For this section, check all that apply.
I often recommend active surveillance for patients with Gleason 6 disease.
I often recommend active surveillance for patients with Gleason 3+4=7 disease.
For patients with oligometastatic disease, I would consider offering stereotactic body radiation therapy to the
oligometastatic lesion outside of a clinical trial.
Please select one of the following options.
Most patients I see in clinic present with intact prostate for discussion of definitive treatment.
Most patients I see in clinic present after prostatectomy for a discussion of adjuvant or salvage radiation.
I see an even balance of patients with intact prostate and those who are post-prostatectomy.
Please select one of the following options.
As a general rule for patients with high risk features, I recommend adjuvant radiation after surgery.
As a general rule for patients with high risk features, I recommend observation and early salvage radiation if
PSA rises.
Please select one of the following options.
For localized high risk prostate cancer, I treat pelvic lymph nodes rarely.
For localized high risk prostate cancer, I treat pelvic lymph nodes often.
Do you consider yourself an expert brachytherapist?
Yes
No
For patients with Gleason 6 disease who desire treatment, with no baseline urinary symptoms and a 40cc prostate,
which would you consider your first choice for treatment?
External beam radiation
Brachytherapy
Either external beam or brachy (no preference)
For patients with localized high risk disease, with no baseline urinary symptoms and a 40cc prostate, which would
you consider your first choice for treatment?
External beam radiation with ADT (androgen deprivation therapy)
External beam radiation with ADT and brachytherapy boost
What is your current practice with regard to digital rectal examinations (DRE)? (Check all that apply)
I routinely perform DRE before treatment
I routinely perform DRE at follow-up visits
I never perform DRE
I believe DRE will change management
I do not believe DRE will change management
What do you consider the default EBRT dose and fractionation for Gleason 3+4 prostate adenocarcinoma?
Conventional fractionation: 78 Gy in 2 Gy fractions, 79.2 Gy in 1.8, or equivalent
Moderate hypofractionation: 70 Gy in 2.5 Gy fractions or equivalent
SBRT/Radical hypofractionation: 5-12 fractions or equivalent
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For each of the following patient scenarios, please enter the lowest PSA value at which you
would order a C-11 PET or PSMA PET.  Enter 0 for "never."
Gleason 4+5=9, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 4+3=7, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 10, T3, intact prostate, pre-treatment __________________________________
Gleason 4+3=7, T2, intact prostate, pre-treatment __________________________________
Gleason 10, T3, post-definitive radiation __________________________________
Gleason 4+3=7, T2, post-definitive radiation __________________________________
In a patient with newly diagnosed cT2 Gleason 9 prostate cancer with a PSA of 200 ng/mL, who has no evidence of
bone metastases by nuclear bone scan and abdominopelvic CT, which of the following would you consider for further
workup?
C-11 PET
PSMA PET
No further workup prior to therapy
Other (specify)
Please specify
 
__________________________________
What are the reasons you do not order PSMA PET or C-11 PET more frequently? (Check all that apply)
Availability
Cost
Lack of evidence
Unsure how to interpret
Other (specify)
Please specify
 
__________________________________
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Are you aware that the NCCN recommends consideration of C-11 choline PET, but not PSMA PET for patients with
prostate cancer?
Yes
No
The NCCN recommends considering C-11 PET in the following scenarios:
- In the setting of detectable PSA after prostatectomy
- Biochemical failure after definitive radiation
- In M0 patients on androgen deprivation therapy with a rising PSA.
What are your thoughts on these recommendations?
I agree with the NCCN recommendations.
The NCCN should recommend the use of C-11 PET in more scenarios than those listed above (specify)
The NCCN should recommend considering C-11 PET in some, but not all of the above scenarios (specify)
The NCCN should not recommend considering C-11 PET at all because there is not enough evidence to
support its use in routine practice.
Please specify
 
__________________________________
Do you think that the NCCN should recommend consideration of PSMA PET?
The NCCN should recommend consideration of PSMA PET in the same scenarios as C-11 PET.
The NCCN should recommend consideration of PSMA PET in more scenarios than C-11 PET (specify).
The NCCN should recommend consideration of PSMA PET in some, but not all of the same scenarios as C-11
PET (specify).
The NCCN should not recommend consideration of PSMA PET because there is not enough evidence to
support its use in routine practice.
Please specify
 
__________________________________
Regarding the comparison of C-11 PET to PSMA PET, select the answer which best describes your opinion.
C-11 PET has better efficacy than PSMA PET.
PSMA PET has better efficacy than C-11 PET.
C-11 PET and PSMA PET have the same level of efficacy.
There is not enough data to know whether C-11 PET or PSMA PET is more effective.
Which of the following imaging studies are available at your practice (or at an affiliated facility)?
C-11 PET
PSMA PET
Both
Neither
What is your current practice with regard to the new imaging modalities PSMA PET and C-11 PET?
I routinely order them for my patients and use the results to guide treatment decision-making.
I have ordered them on rare occasion for my patients and used the results to guide treatment
decision-making.
I do not order them, but if a patient already has results at the time I see them, I will use the results to guide
treatment decision-making.
I do not order them and do not use the results to guide treatment decision-making.
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For each of the following patient scenarios, please enter the lowest PSA value at which you
would order a C-11 PET or PSMA PET.  Enter 0 for "never."
Gleason 4+5=9, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 4+3=7, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 10, T3, intact prostate, pre-treatment __________________________________
Gleason 4+3=7, T2, intact prostate, pre-treatment __________________________________
Gleason 10, T3, post-definitive radiation __________________________________
Gleason 4+3=7, T2, post-definitive radiatio __________________________________
I  a patient with newly diagnosed cT2 Gleason 9 prostate cancer with a PSA of 200 ng/mL, who has no evidence of
bone metastases by nuclear bone scan and abdominopelvic CT, which of the following would you consider for further
workup?
C-11 PET
PSMA PET
No further workup prior to therapy
Other (specify)
Please specify
 
__________________________________
What are the reasons you do not order PSMA PET or C-11 PET more frequently? (Check all that apply)
Availability
Cost
Lack of evidence
Unsure how to interpret
Other (specify)
Please specify
 
__________________________________
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What is your current practice with regard to the new imaging modalities PSMA PET and C-11 PET?
I often refer patients to centers capable of performing one of these tests.
On rare occasions I have referred my patients to centers capable of performing one of these tests.
I do not refer them, but if a patient already has results at the time I see them, I will use the results to guide
treatment decision-making.
I do not refer them and do not use the results to guide treatment decision-making.
What is the primary reason you do not use results from PSMA PET or C-11 PET to guide treatment decision-making?
There is not enough data to guide usage of these tests.
I do not believe these tests are effective.
I lack personal experience using these tests.
Other (specify)
Please specify
 
__________________________________
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For each of the following patient scenarios, please enter the lowest PSA value at which you
would order a C-11 PET or PSMA PET.  Enter 0 for "never."
Gleason 4+5=9, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 4+3=7, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 10, T3, intact prostate, pre-treatment __________________________________
Gleason 4+3=7, T2, intact prostate, pre-treatment __________________________________
Gleason 10, T3, post-definitive radiation __________________________________
Gleason 4+3=7, T2, post-definitive radiation __________________________________
In a patient with newly diagnosed cT2 Gleason 9 prostate cancer with a PSA of 200 ng/mL, who has no evidence of
bone metastases by nuclear bone scan and abdominopelvic CT, which of the following would you consider for further
workup?
C-11 PET
PSMA PET
No further workup prior to therapy
Other (specify)
Please specify
 
__________________________________
What are the reasons you do not order PSMA PET or C-11 PET more frequently? (Check all that apply)
Availability
Cost
Lack of evidence
Unsure how to interpret
Other (specify)
Please specify
 
__________________________________
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For each of the following patient scenarios, please enter the lowest PSA value at which you
would order a C-11 PET or PSMA PET.  Enter 0 for "never."
Gleason 4+5=9, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 4+3=7, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 10, T3, intact prostate, pre-treatment __________________________________
Gleason 4+3=7, T2, intact prostate, pre-treatment __________________________________
Gleason 10, T3, post-definitive radiation __________________________________
Gleason 4+3=7, T2, post-definitive radiation __________________________________
In a patient with newly diagnosed cT2 Gleason 9 prostate cancer with a PSA of 200 ng/mL, who has no evidence of
bone metastases by nuclear bone scan and abdominopelvic CT, which of the following would you consider for further
workup?
C-11 PET
PSMA PET
No further workup prior to therapy
Other (specify)
Please specify
 
__________________________________
What are the reasons you do not order PSMA PET or C-11 PET more frequently? (Check all that apply)
Availability
Cost
Lack of evidence
Unsure how to interpret
Other (specify)
Please specify
 
__________________________________
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For each of the following patient scenarios, please enter the lowest PSA value at which you
would order a C-11 PET or PSMA PET.  Enter 0 for "never."
Gleason 4+5=9, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 4+3=7, post-prostatectomy, consecutively __________________________________
rising PSA
Gleason 10, T3, intact prostate, pre-treatment __________________________________
3 7 T2, intact pros ate, pre-tr atment
Gleason 10, T3, post-definitive radiation __________________________________
Gleason 4+3=7, T2, post-definitive radiation __________________________________
In a patient with ewly diagnosed cT2 Gleason 9 prostate cancer with a PSA of 200 ng/mL, who has no evidence of
bone metastases by nuclear bone scan and abdominopelvic CT, which of the following would you consider for further
workup?
C-11 PET
PSMA PET
No further workup prior to therapy
Other (specify)
Please specify
 
__________________________________
What are the reasons you do not order PSMA PET or C-11 PET more frequently? (Check all that apply)
Availability
Cost
Lack of evidence
Unsure how to interpret
Other (specify)
Ple se specify
 
__________________________________
